ClinicalTrials.gg

Program

HRS-5632

A development code. Also written as “HRS-5632 Injection”.

Its studies are mostly in Dyslipidemias, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Sep 15, 20252 company-led studies, 1 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine21 open or runningphase 2since Sep 15, 2025Nov 12, 2024Apr 2027phase 2 · NCT07185776
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-5632, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2024First study: phase 1 study in DyslipidemiasFirst studyNCT06732154 · 50 enrolled · China
  2. Sep 15, 2025Phase 2 study in Lipoprotein DisorderNCT07185776 · 203 enrolled · China

Ahead

  1. Apr 2027Primary completion: phase 2 study in Lipoprotein DisorderNCT07185776

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07185776Lipoprotein Disorder · China2Active, not recruitingApr 2027203
NCT06732154Dyslipidemias · China1CompletedMar 2, 202650

How it is read

Names in the registry

  • “HRS-5632”, 1 entry
  • “HRS-5632 Injection”, 1 entry

Codes read as this program: HRS5632.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.